Immunizations could be administered within minutes where and when a disease is breaking out.
Vaccines combat diseases and protect populations from outbreaks, but the life-saving technology leaves room for improvement. Vaccines usually are made en masse in centralized locations far removed from where they will be used. They are expensive to ship and keep refrigerated and they tend to have short shelf lives.
University of Washington engineers hope a new type of vaccine they have shown to work in mice will one day make it cheaper and easy to manufacture on-demand vaccines for humans. Immunizations could be administered within minutes where and when a disease is breaking out.
“We’re really excited about this technology because it makes it possible to produce a vaccine on the spot. For instance, a field doctor could see the beginnings of an epidemic, make vaccine doses right away, and blanket vaccinate the entire population in the affected area to prevent the spread of an epidemic,” said François Baneyx, a UW professor of chemical engineering and lead author of a recent paper published online in the journal Nanomedicine.
The research was funded by a Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation and the National Institutes of Health.
In typical vaccines, weakened pathogens or proteins found on the surface of microbes and viruses are injected into the body along with compounds called adjuvants to prepare a person’s immune system to fight a particular disease. But standard formulations don’t always work, and the field is seeking ways to manufacture vaccines quicker, cheaper and tailored to specific infectious agents, Baneyx said.
The UW team injected mice with nanoparticles synthesized using an engineered protein that both mimics the effect of an infection and binds to calcium phosphate, the inorganic compound found in teeth and bones. After eight months, mice that contracted the disease made threefold the number of protective “killer” T-cells – a sign of a long-lasting immune response – compared with mice that had received the protein but no calcium phosphate nanoparticles.
The nanoparticles appear to work by ferrying the protein to the lymph nodes where they have a higher chance of meeting dendritic cells, a type of immune cell that is scarce in the skin and muscles, but plays a key role in activating strong immune responses.
In a real-life scenario, genetically engineered proteins based on those displayed at the surface of pathogens would be freeze-dried or dehydrated and mixed with water, calcium and phosphate to make the nanoparticles. This should work with many different diseases and be especially useful for viral infections that are hard to vaccinate against, Baneyx said.
He cautioned, however, that it has only been proven in mice, and the development of vaccines using this method hasn’t begun for humans.
Read more . . .
The Latest on: On-demand vaccines
Why this Seattle mom finally got her kids vaccinated after years of saying no - KUOW News and Information
April 18, 2019 - Why this Seattle mom finally got her kids vaccinated after years of saying no KUOW News and InformationBut she recently told them it was time. Her son, Xaven, age 11, described the scene: “She was like, we're gonna have to get vaccinated on Wednesday, okay?
Public Health How Can We Increase Trust in Vaccines? - Scientific American
April 15, 2019 - Public Health How Can We Increase Trust in Vaccines? Scientific AmericanIn the early 90s, I was a pediatrician working in a small town in my home state of Gujarat, India when a wave of polio cases hit the state. This outbreak was on a ...
'A desecration of memory' | The Jewish Standard - The Jewish Standard
April 18, 2019 - 'A desecration of memory' | The Jewish Standard The Jewish StandardThe measles outbreak, both here and across the country, continues; it's been particularly virulent in Rockland County. It's particularly evident in some parts of the ...
Global Vaccine Market Expected to Reach $64,538.4 Million in 2027 - R & D Magazine
April 18, 2019 - Global Vaccine Market Expected to Reach $64,538.4 Million in 2027 R & D MagazineThe global vaccines market is expected to reach US$ 64,538.4 Mn in 2027 from US$ 36,998.8 in 2018. The market is estimated to grow with a CAGR of 6.5 ...
Further advances in cell-based influenza vaccine technology announced - European Pharmaceutical Review
April 17, 2019 - Further advances in cell-based influenza vaccine technology announced European Pharmaceutical ReviewAn influenza vaccine manufacturer has announced it is filing an Annual Strain Update with the US FDA due to advances in influenza vaccine technology.
‘Parents call the shots.’ Group rallies to demand vaccine choice - Houston Chronicle
March 28, 2019 - ‘Parents call the shots.’ Group rallies to demand vaccine choice Houston Chronicle On the South steps of the Texas Capitol, state Rep. Briscoe Cain prayed that the children standing beside him would not be mocked for their parents' decision ...
Friday, April 19, 2019 - Kaiser Health News
April 19, 2019 - Friday, April 19, 2019 Kaiser Health NewsPotentially deadly fatty liver disease, linked to overconsumption of sugar in drinks and food, often starts in childhood. The goal: Get children to change their ...
Fear, resentment — and more demand for vaccines as one Washington county grapples with measles outbreak - The Seattle Times
March 30, 2019 - Fear, resentment — and more demand for vaccines as one Washington county grapples with measles outbreak The Seattle TimesFor a solid month, Ashley Matzie took her newborn almost nowhere. Not to the grocery store, or to the park or even for a walk on her block in Camas, Washington ...
A Shot in the Arm for Vaccine Manufacturing - Genetic Engineering & Biotechnology News
April 1, 2019 - A Shot in the Arm for Vaccine Manufacturing Genetic Engineering & Biotechnology NewsVaccine science has come a long way since the 18th century, when Edward Jenner used pus from a milkmaid's sore to stop a child from catching smallpox.1 ...
New Research Coverage Highlights Turquoise Hill Resources, GDS HOLDINGS, AptarGroup, VBI Vaccines, Loral Space and Communications, and FEDNAT HOLDING CO — Consolidated Revenues, Company Growth, and Expectations for 2019 - Associated Press
April 19, 2019 - New Research Coverage Highlights Turquoise Hill Resources, GDS HOLDINGS, AptarGroup, VBI Vaccines, Loral Space and Communications, and FEDNAT HOLDING CO — Consolidated Revenues, Company Growth, and Expectations for 2019 Associated PressPress release *content* from Globe Newswire. The AP news staff was not involved in its creation.